TRCT
CTSO icon

Tower Research Capital (TRC)’s Cytosorbents Corp CTSO Stock Holding History

Tower Research Capital (TRC)’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,170
Closed -$1.39K – 5185
2025
Q4 		$1.39K Sell
2,170
-3,437
-61% -$2.64K ﹤0.01% 4702
2025
Q3 		$5.24K Buy
5,607
+4,069
+265% +$4.01K ﹤0.01% 4255
2025
Q2 		$1.97K Sell
1,538
-3,965
-72% -$3.98K ﹤0.01% 4716
2025
Q1 		$5.5K Buy
5,503
+3,408
+163% +$3.59K ﹤0.01% 4118
2024
Q4 		$1.91K Sell
2,095
-886
-30% -$870 ﹤0.01% 4941
2024
Q3 		$4.47K Sell
2,981
-18,718
-86% -$20.5K ﹤0.01% 4534
2024
Q2 		$15.3K Buy
21,699
+13,675
+170% +$11.9K ﹤0.01% 3916
2024
Q1 		$7.62K Buy
8,024
+1,869
+30% +$1.82K ﹤0.01% 4176
2023
Q4 		$6.83K Buy
6,155
+5,352
+667% +$7.95K ﹤0.01% 4693
2023
Q3 		$1.51K Buy
803
+657
+450% +$1.89K ﹤0.01% 5317
2023
Q2 		$524 Buy
+146
New +$462 ﹤0.01% 5606
2022
Q4 		– Sell
-958
Closed -$1K – 5949
2022
Q3 		$1K Buy
+958
New +$1.87K ﹤0.01% 5745
2022
Q2 		– Sell
-6,829
Closed -$22K – 6130
2022
Q1 		$22K Sell
6,829
-28,175
-80% -$101K ﹤0.01% 3427
2021
Q4 		$146K Buy
35,004
+6,557
+23% +$36.8K ﹤0.01% 1987
2021
Q3 		$231K Sell
28,447
-327
-1% -$2.66K 0.01% 1682
2021
Q2 		$218K Buy
28,774
+24,296
+543% +$205K 0.01% 1848
2021
Q1 		$39K Sell
4,478
-109
-2% -$1.04K ﹤0.01% 3329
2020
Q4 		$36K Sell
4,587
-32,633
-88% -$273K ﹤0.01% 3416
2020
Q3 		$297K Buy
37,220
+30,574
+460% +$276K ﹤0.01% 2198
2020
Q2 		$66K Buy
+6,646
New +$61K ﹤0.01% 2826
2020
Q1 		– Sell
-3,972
Closed -$15K – 3175
2019
Q4 		$15K Buy
3,972
+1,706
+75% +$7.44K ﹤0.01% 2095
2019
Q3 		$11K Sell
2,266
-664
-23% -$3.86K ﹤0.01% 2860
2019
Q2 		$20K Sell
2,930
-2,514
-46% -$17.3K ﹤0.01% 2172
2019
Q1 		$41K Buy
5,444
+4,851
+818% +$37.8K ﹤0.01% 1865
2018
Q4 		$5K Buy
+593
New +$5.89K ﹤0.01% 2887
2018
Q2 		– Sell
-1,072
Closed -$8K – 3703
2018
Q1 		$8K Buy
1,072
+294
+38% +$2.22K ﹤0.01% 2536
2017
Q4 		$5K Buy
+778
New +$4.95K ﹤0.01% 2872
2017
Q3 		– Sell
-68
Closed – – 3822
2017
Q2 		$0 Sell
68
-32
-32% -$140 ﹤0.01% 2818
2017
Q1 		$0 Sell
100
-1,340
-93% -$7.49K ﹤0.01% 3182
2016
Q4 		$8K Buy
1,440
+1,359
+1,678% +$7.44K ﹤0.01% 2765
2016
Q3 		$1K Sell
81
-613
-88% -$3.19K ﹤0.01% 3274
2016
Q2 		$3K Sell
694
-761
-52% -$3.31K ﹤0.01% 3671
2016
Q1 		$5K Sell
1,455
-1,528
-51% -$6.63K ﹤0.01% 2664
2015
Q4 		$17K Buy
2,983
+2,823
+1,764% +$19.2K ﹤0.01% 1458
2015
Q3 		$1K Sell
160
-41
-20% -$273 ﹤0.01% 3584
2015
Q2 		$1K Sell
201
-299
-60% -$2.03K ﹤0.01% 3972
2015
Q1 		$7K Buy
+500
New +$5.14K ﹤0.01% 3032

Other funds holding CTSO

AC
Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SC
Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Tower Research Capital (TRC)'s CTSO Position: Q1 2026 in Review

Tower Research Capital (TRC) sold out of Cytosorbents Corp (CTSO) in Q1 2026, closing a stake of 2,170 shares — an estimated $1.39K sold.

Tower Research Capital (TRC) first reported a position in CTSO in Q1 2015 and held it in 37 quarters. The position peaked at $297K in Q3 2020. 50 funds tracked by Wall St. Rank hold CTSO as of Q1 2026.

  • Tower Research Capital (TRC) reported no remaining Cytosorbents Corp position as of Q1 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 2,170 Cytosorbents Corp shares in Q1 2026, an estimated $1.39K.
  • Tower Research Capital (TRC) first reported a position in Cytosorbents Corp in Q1 2015 and held it in 37 quarters.
  • Tower Research Capital (TRC)'s Cytosorbents Corp position peaked at $297K in Q3 2020.
  • 50 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.